stay updated with our newsletter

Mayo Clinicians’ Guide to Cannabidiol and Hemp Oil

cannabidiol and hemp oil

In this summary-scientific review from Mayo Clinical Proceedings, the researchers provide an overview of the scientific work on cannabidiol and hemp oil and the distinction between marijuana, hemp, and the different components of CBD and hemp oil products. They summarize the current legal status of CBD and hemp oils inRead

Could the Endocannabinoid System Offer a New Treatment Target for Obsessive Compulsive Disorder?

THC or CBD Content

The disabling condition of obsessive-compulsive disorder (OCD) affects about 2–3% of people worldwide. Evidence suggests that abnormalities in cortico-striatal-thalamic-cortical circuitry and specific gene variants contribute to the pathogenesis of the disorder. This latest study, published in Cannabis and Cannabinoid Research, suggests that the endocannabinoid system (ECS) plays a role in OCD symptomsRead

International Cannabinoid Research Society (ICRS) Names Cannabis and Cannabinoid Research Its Official Journal

Cannabis and Cannabinoid Research

New Rochelle, NY, May 7, 2019—Cannabis and Cannabinoid Research (CCR) is extremely excited to announce that the International Cannabinoid Research Society (ICRS) has named CCR its Official Journal. The ICRS is a foremost international society spearheading scientific research in all fields of cannabinoids, ranging from biochemical, chemical, and physiological studiesRead

Interaction of Neurotransmitters and Neurochemicals with Lymphocytes, including the Endocannabinoid System

Neurotransmitters and neurochemicals

Neurotransmitters and neurochemicals can act on lymphocytes by binding to receptors expressed by lymphocytes. This review describes lymphocyte expression of receptors for a selection of neurotransmitters and neurochemicals, the anatomical locations where lymphocytes can interact with neurotransmitters, and the effects of the neurotransmitters on lymphocyte function. Implications for health andRead

Safety and Efficacy of Medical Cannabis in Elderly Patients: A Retrospective Review in a Neurological Outpatient Setting

Medical Cannabis in Elderly Patients

As more states legalize medical cannabis, clinicians are seeking more information on how it may affect elderly populations for chronic conditions associated with aging. In this study, published in the journal Neurology, researchers evaluated medical cannabis’ (MC) efficacy and adverse effects (AE) in patients 75 years of age or older.Read

New Study on the Endocannabinoid System and Stroke

Stroke is an important cause of morbidity and mortality worldwide. Development of novel neuroprotectants is of paramount importance. This review, on the endocannabinoid system and stroke, seeks to summarize the recent evidence for the role of the endocannabinoid signaling system in stroke pathophysiology, as well as the evidence from preclinical

Read more

FDA Commissioner Scott Gottlieb, M.D. on Public Hearing for Cannabis-containing and Cannabis-derived Products

Legal Cannabis

 Statement from FDA Commissioner Scott Gottlieb, M.D., on new steps to advance agency’s continued evaluation of potential regulatory pathways for cannabis-containing and cannabis-derived products In recent years, we’ve seen a growing interest in the development of therapies and other FDA-regulated consumer products derived from cannabis (Cannabis sativa L.) and itsRead

JOIN OUR MAILING LIST

Weekly round-up, access to thought leaders, and articles to help you improve health outcomes and the success of your practice.